A Study of RC148 in Patients With Locally Advanced Unresectable or Metastatic Malignant Solid Tumors
Status:
Recruiting
Trial end date:
2025-12-31
Target enrollment:
Participant gender:
Summary
This trial is to evaluate the safety, tolerability, maximum tolerated dose (MTD) / maximum
administered dose (MAD), pharmacokinetics (PK), pharmacodynamics, immunogenicity and
recommended Phase 2 dose (RP2D) of RC148 in participants with locally advanced unresectable
or metastatic solid tumors.In addition, the preliminary anti-tumour efficacy of RC148 as
single agent will be assessed.